I did a more in-depth reading of your first source
It is accurate that the antibody test are predicated exclusively on the receptor binding domain (RBD) of the spike (S) protein of SARS-CoV-2.
More reading about the antibody test.
The first study you cited had this to say about the immune systems antibody robustness for vaccinated vs. natural infection (With the known caveat that natural infection is much more risky than a vaccine)
https://www.medrxiv.org/content/10.1101/2021.07.07.21259499v1.full said:
In agreement with previous studies, levels of IgG serum antibodies elicited by the mRNA vaccine were significantly higher than those of convalescent individuals11,15,16 and inversely correlated with age17 (Fig 3).
The immune system as measured by antibody tests does react stronger to vaccines than symptomatic or asymptomatic natural infection, but if you read further.
They developed a vaccine that ONLY targets the spike protein. Then they devised an antibody test that ONLY measures seropositivity for a response to the spike protein and compared this antibody test to the immune systems response which includes 3 other mechanisms of identifying pathogens.
It makes sense that the immune system would react stronger to a pathogen containing only the spike protein (vaccine) than the virus which has the spike protein and also the other mechanisms (membrane, envelope, nucleotide). To make a fair comparison of vaccines to natural infection, they would need to develop an antibody test that measures the other three indicators of the immune systems response. It is already known that the vaccine would test no titers for these three additional tests.
The first study you presented even acknowledges this about the antibody tests being used to draw the conclusion that vaccines are better than natural infection:
https://www.medrxiv.org/content/10.1101/2021.07.07.21259499v1.full said:
The serum anti-RBD IgG antibodies that were assayed are highly accurate markers of infection10 and strongly correlate with neutralizing activity11 and disease severity7, but can not be used as sole predictors of anti-SARS-CoV-2 neutralizing ability12.
Which is to say there is more to know and explore. This study mentions one aspect of these unknowns:
https://www.medrxiv.org/content/10.1101/2021.07.07.21259499v1.full said:
Convalescent individuals recovering from symptomatic COVID-19 typically have low plasma titres of RBD-specific antibodies, however, the antigen-specific memory B cells that facilitate the antibody response, maintain and enhance their potency for years11,13,14.
One the other hand, longevity of protection,
If you look at figure 3. The trend of the antibody titers of the vaccinated (which are falling fast) will eventually fall below natural symptomatic infected individuals (which is holding steady). These two lines are most likely to cross-over between 120 to 130 days.